ARIUS Adds Expert in Basic Cancer Research to Scientific Advisory Board

TSX Venture: ARI

TORONTO, June 13 /CNW/ - ARIUS Research Inc. (TSX-VE: ARI) announced
today that Dr. Robert Kerbel one of the Canada's best known and accomplished
cancer researchers, has joined their Scientific Advisory Board (SAB).
Dr. Kerbel is internationally recognized for his achievements in many
areas, most notably for helping to uncover the basis of new blood vessel
formation in tumors ("tumor angiogenesis") and contributing to the development
of "metronomic chemotherapy" concept, an innovative antiangiogenic therapeutic
approach designed to reduce toxicity while maintaining or enhancing efficacy
of chemotherapy treatments for cancer. He has received numerous career awards
including a Research Scholar and then Associate award from the National Cancer
Institute of Canada (NCIC), and was named a Terry Fox Research Scientist of
the NCIC. In 2001, he was awarded a prestigious Canada Research Chair in
Molecular Medicine, and last year he was awarded the Robert Noble Prize for
excellence in cancer research by the NCIC. Dr. Kerbel has published over 270
scientific papers and given over 700 invited scientific lectures since 1975.
"We are very pleased to have Dr. Kerbel as part of our advisory team"
said Dr. David Young, President and CSO. "His strengths will help broaden our
pre-clinical research efforts in keeping with our business model and will
compliment the expertise of the other members of our scientific advisory
board."
Dr. Kerbel joins Dr. Robert Dillman, Director of Clinical and Laboratory
Research and Medical Director of the Hoag Cancer Centre, Dr. Steven Gallinger
Professor of Surgery at the University of Toronto and a member of the
Department of Laboratory Medicine and Pathobiology at Mount Sinai and Princess
Margaret Hospitals and Dr. David Hyams, Medical Director, Aptium Oncology.

About ARIUS Research

ARIUS Research Inc. is a biotechnology company dedicated to the discovery
and development of novel anticancer monoclonal antibodies (MAbs). Established
in 1999, ARIUS has built a proprietary technology platform, FunctionFIRST(TM),
that rapidly identifies powerful MAbs targeting a variety of cancer
indications. This antibody generation engine has enabled ARIUS to assemble a
growing pipeline of over 250 functional MAbs, which may be used for commercial
collaborations, out-licensing or in-house development. ARIUS has ongoing
licensing and research partnerships with key biotechnology and drug
development companies that provide revenues and access to external
technologies. The long-term vision of ARIUS is to deliver personalized therapy
by matching multiple antibodies to the distinct antigenic characteristics of
each patient's tumor cells thereby increasing efficacy and avoiding side
effects. ARIUS is listed on the TSX Venture Exchange under the symbol "ARI".

Forward-Looking Statement

Certain statements in this news release constitute "forward-looking
statements" within the meaning of the Private Securities Litigation Reform
Act of 1995, which involve known and unknown risks, uncertainties and other
factors that may cause our actual results to be materially different from any
future results, performance or achievements expressed or implied by such
statements. Forward-looking statements in this release include, but are not
limited to, ARIUS successfully advancing its new product programs as well as
licensing opportunities. These statements are only predictions and actual
events or results may differ materially. Factors that could cause such actual
events or results expressed or implied by such forward-looking statements to
differ materially from any future results expressed or implied by such
statements include, but are not limited to: early stage of development;
technology and product development; dependence on and management of current
and future corporate collaborations; future capital needs; uncertainty of
additional funding; no assurance of market acceptance; dependence on
proprietary technology and uncertainty of patent protection; intense
competition; manufacturing and market uncertainties; and government
regulation. These and other factors are described in detail in the Company's
Annual Report, forthcoming news releases and other filings with Canadian
securities regulatory authorities and the U.S. Securities & Exchange
Commission. Forward-looking statements are based on our current expectations
and ARIUS is not obligated to update such information to reflect later events
or developments.

Website: www.ariusresearch.com

The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this statement.